Company Profile
Roivant Stock Price, News & Catalysts
- Ticker:
- ROIV
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
36.30 USD (-1.47%)
Close
Last updated: August 21, 2026
20.3B USD
Market cap
Why the stock is moving
As of Aug 21, 2026, ROIV closed down 1.47% at $36.30. No new same-company headline was identified in the current news window.
Company overview
Vant Operating Model
Roivant develops and commercializes medicines through focused subsidiaries known as Vants. The structure gives individual programs dedicated teams while retaining access to the parent company's capital, development and commercialization capabilities.
Brepocitinib Autoimmune Franchise
Brepocitinib is an oral JAK1/TYK2 inhibitor under FDA review for dermatomyositis. Priovant is also developing it in late-stage studies for non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris.
IMVT-1402
Immunovant's IMVT-1402 is a fully human anti-FcRn antibody for IgG-mediated autoimmune diseases. Its clinical portfolio spans Graves' disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, Sjogren's disease and cutaneous lupus erythematosus.
Mosliciguat
Pulmovant is developing mosliciguat, an inhaled soluble guanylate-cyclase activator, for pulmonary hypertension associated with interstitial lung disease.
RNA-Delivery Intellectual Property
Genevant contributes lipid-nanoparticle technology and an associated intellectual-property portfolio for RNA delivery, adding a technology-licensing and patent-enforcement component to Roivant's operating model.
Future catalysts
- Commercial launch of brepocitinib in dermatomyositis by the end of September 2026, subject to FDA approval.
- Topline Phase 3 data for brepocitinib in non-infectious uveitis in the second half of 2026.
- Topline proof-of-concept data for IMVT-1402 in cutaneous lupus erythematosus in the second half of 2026.
- Topline Phase 2 data for mosliciguat in PH-ILD in the second half of 2026.
- Topline data from potentially registrational IMVT-1402 studies in Graves' disease and myasthenia gravis in 2027.
- Topline data from the brepocitinib Phase 3 cutaneous-sarcoidosis study and IMVT-1402 studies in CIDP and Sjogren's disease in 2028.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Roivant (ROIV)?
Roivant (ROIV) most recently closed at 36.30 USD, a -1.47% move versus the previous session.
What is the market cap of Roivant (ROIV)?
Roivant currently has a market capitalization of 20.3B USD on BioPharmSignal.
What does Roivant do?
Vant Operating Model Roivant develops and commercializes medicines through focused subsidiaries known as Vants. The structure gives individual programs dedicated teams while retaining access to the parent company's capital, development and commercialization capabilities. Brepocitinib Autoimmune Franchise Brepocitinib is an oral JAK1/TYK2 inhibitor under FDA...
On which exchange is ROIV stock listed?
Roivant (ROIV) is associated with NASDAQ, United States, Biopharma.
What is IMVT-1402?
Topline proof-of-concept data for IMVT-1402 in cutaneous lupus erythematosus in the second half of 2026.
Which conditions is Roivant targeting with IMVT-1402?
Topline proof-of-concept data for IMVT-1402 in cutaneous lupus erythematosus in the second half of 2026.
How does Roivant describe recent progress with IMVT-1402?
Topline proof-of-concept data for IMVT-1402 in cutaneous lupus erythematosus in the second half of 2026.
What is PH-ILD?
Topline Phase 2 data for mosliciguat in PH-ILD in the second half of 2026.